Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 41 articles:
HTML format
Text format



Single Articles


    February 2017
  1. SHI T, Wang P, Xie C, Yin S, et al
    BRCA1 and BRCA2 mutations in ovarian cancer patients from China: Ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.
    Int J Cancer. 2017 Feb 8. doi: 10.1002/ijc.30633.
    PubMed     Text format     Abstract available


    January 2017
  2. PRAESTEGAARD C, Jensen A, Jensen SM, Nielsen TS, et al
    Cigarette smoking is associated with adverse survival among women with ovarian cancer: results from a pooled analysis of 19 studies.
    Int J Cancer. 2017 Jan 7. doi: 10.1002/ijc.30600.
    PubMed     Text format     Abstract available


    October 2016
  3. TRABERT B, Eldridge RC, Pfeiffer RM, Shiels MS, et al
    Pre-diagnostic circulating inflammation markers and endometrial cancer risk in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.
    Int J Cancer. 2016 Oct 22. doi: 10.1002/ijc.30478.
    PubMed     Text format     Abstract available


  4. PERES LC, Bandera EV, Qin B, Guertin KA, et al
    Dietary Inflammatory Index and Risk of Epithelial Ovarian Cancer in African American Women.
    Int J Cancer. 2016 Oct 11. doi: 10.1002/ijc.30467.
    PubMed     Text format     Abstract available


    September 2016
  5. HARRIS HR, Titus LJ, Cramer DW, Terry KL, et al
    Long and irregular menstrual cycles, polycystic ovary syndrome, and ovarian cancer risk in a population-based case-control study.
    Int J Cancer. 2016 Sep 26. doi: 10.1002/ijc.30441.
    PubMed     Text format     Abstract available


  6. KRAUS C, Hoyer J, Vasileiou G, Wunderle M, et al
    Gene panel sequencing in familial Breast/Ovarian Cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
    Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30428.
    PubMed     Text format     Abstract available


    August 2016
  7. VOLOSHIN T, Munster M, Blatt R, Shteingauz A, et al
    Alternating Electric Fields (TTFields) in Combination with Paclitaxel are Therapeutically Effective against Ovarian Cancer Cells in vitro and in vivo.
    Int J Cancer. 2016 Aug 25. doi: 10.1002/ijc.30406.
    PubMed     Text format     Abstract available


    July 2016
  8. LEE AW, Bomkamp A, Bandera EV, Jensen A, et al
    A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer.
    Int J Cancer. 2016 Jul 15. doi: 10.1002/ijc.30274.
    PubMed     Text format     Abstract available


    June 2016
  9. ALSINA-SANCHIS E, Figueras A, Lahiguera A, Vidal A, et al
    The TGFbeta pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels.
    Int J Cancer. 2016 Jun 14. doi: 10.1002/ijc.30233.
    PubMed     Text format     Abstract available


    May 2016
  10. OREN R, Addadi Y, Narunsky Haziza L, Dafni H, et al
    Fibroblast recruitment as a tool for ovarian cancer detection and targeted therapy.
    Int J Cancer. 2016 May 31. doi: 10.1002/ijc.30209.
    PubMed     Text format     Abstract available


  11. KELLY Z, Moller-Levet C, McGrath S, Butler-Manuel S, et al
    The prognostic significance of specific HOX gene expression patterns in ovarian cancer.
    Int J Cancer. 2016 May 26. doi: 10.1002/ijc.30204.
    PubMed     Text format     Abstract available


    April 2016
  12. CIRILLO PM, Wang ET, Cedars MI, Chen LM, et al
    Irregular menses predicts ovarian cancer: Prospective evidence from the Child Health and Development Studies.
    Int J Cancer. 2016 Apr 15. doi: 10.1002/ijc.30144.
    PubMed     Text format     Abstract available


    March 2016
  13. BANDERA EV, Qin B, Moorman PG, Alberg AJ, et al
    Obesity, weight gain, and ovarian cancer risk in African American women.
    Int J Cancer. 2016 Mar 31. doi: 10.1002/ijc.30115.
    PubMed     Text format     Abstract available


  14. HUANG T, Poole EM, Eliassen AH, Okereke OI, et al
    Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer.
    Int J Cancer. 2016 Mar 2. doi: 10.1002/ijc.30066.
    PubMed     Text format     Abstract available


    January 2016
  15. RUSSELL MR, Walker MJ, Williamson AJ, Gentry-Maharaj A, et al
    Protein Z: A putative novel biomarker for early detection of ovarian cancer.
    Int J Cancer. 2016 Jan 27. doi: 10.1002/ijc.30020.
    PubMed     Text format     Abstract available


  16. ALTMAN D, Yin L, Falconer H
    Long-term cancer risk after hysterectomy on benign indications: population-based cohort study.
    Int J Cancer. 2016 Jan 21. doi: 10.1002/ijc.30011.
    PubMed     Text format     Abstract available


    November 2015
  17. KUROSAKI A, Hasegawa K, Kato T, Abe K, et al
    Serum folate receptor alpha (FRA) as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression.
    Int J Cancer. 2015 Nov 23. doi: 10.1002/ijc.29937.
    PubMed     Text format     Abstract available


    October 2015
  18. YANG X, Shen J, Gao Y, Feng Y, et al
    Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis.
    Int J Cancer. 2015;137:2029-39.
    PubMed     Text format     Abstract available


  19. QUARTUCCIO SM, Karthikeyan S, Eddie SL, Lantvit DD, et al
    Mutant p53 expression in fallopian tube epithelium drives cell migration.
    Int J Cancer. 2015;137:1528-38.
    PubMed     Text format     Abstract available


    September 2015
  20. GAITSKELL K, Green J, Pirie K, Reeves G, et al
    Tubal ligation and ovarian cancer risk in a large cohort: Substantial variation by histological type.
    Int J Cancer. 2015 Sep 17. doi: 10.1002/ijc.29856.
    PubMed     Text format     Abstract available


  21. HUANG T, Eliassen AH, Hankinson SE, Okereke OI, et al
    A prospective study of leisure-time physical activity and risk of incident epithelial ovarian cancer: Impact by menopausal status.
    Int J Cancer. 2015 Sep 3. doi: 10.1002/ijc.29834.
    PubMed     Text format     Abstract available



  22. Erratum-ovarian cancer cells, not normal cells, are damaged by mirk/dyrk1b kinase inhibition.
    Int J Cancer. 2015;137:E13.
    PubMed     Text format    


    August 2015
  23. GANAPATHI MK, Jones WD, Sehouli J, Michener CM, et al
    Expression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high grade serous ovarian cancer.
    Int J Cancer. 2015 Aug 27. doi: 10.1002/ijc.29815.
    PubMed     Text format     Abstract available


  24. PERMUTH-WEY J, Fulp WJ, Reid BM, Chen Z, et al
    STAT3 Polymorphisms May Predict an Unfavorable Response to First-Line Platinum-based Therapy for Women with Advanced Serous Epithelial Ovarian Cancer.
    Int J Cancer. 2015 Aug 11. doi: 10.1002/ijc.29799.
    PubMed     Text format     Abstract available


    July 2015
  25. HAFNER N, Steinbach D, Jansen L, Diebolder H, et al
    RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer.
    Int J Cancer. 2015 Jul 15. doi: 10.1002/ijc.29690.
    PubMed     Text format     Abstract available


  26. DENT BM, Ogle LF, O'Donnell RL, Hayes N, et al
    High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers.
    Int J Cancer. 2015 Jul 14. doi: 10.1002/ijc.29680.
    PubMed     Text format     Abstract available


    June 2015
  27. COCCO E, Shapiro EM, Gasparrini S, Lopez S, et al
    Clostridium Perfringens Enterotoxin C-terminal domain labeled to fluorescent Dyes for in vivo visualization of micro-metastatic chemotherapy-resistant ovarian cancer.
    Int J Cancer. 2015 Jun 9. doi: 10.1002/ijc.29632.
    PubMed     Text format     Abstract available


    April 2015
  28. GOUNDIAM O, Gestraud P, Popova T, De la Motte Rouge T, et al
    Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non-BRCAness high grade ovarian carcinoma.
    Int J Cancer. 2015 Apr 17. doi: 10.1002/ijc.29568.
    PubMed     Text format     Abstract available


    March 2015
  29. FARKKILA A, Koskela S, Bryk S, Alfthan H, et al
    The clinical utility of serum Anti-Mullerian hormone in the follow-up of ovarian adult-type granulosa cell tumors - a comparative study with inhibin B.
    Int J Cancer. 2015 Mar 24. doi: 10.1002/ijc.29532.
    PubMed     Text format     Abstract available


  30. KRATOCHVILOVA K, Horak P, Esner M, Soucek K, et al
    Tumor suppressor candidate 3 (TUSC3) prevents the epithelial-to-mesenchymal transition and inhibits tumor growth by modulating the endoplasmic reticulum stress response in ovarian cancer cells.
    Int J Cancer. 2015 Mar 3. doi: 10.1002/ijc.29502.
    PubMed     Text format     Abstract available


    February 2015
  31. FORTNER RT, Ose J, Merritt MA, Schock H, et al
    Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness, and histologic subtypes: Results from the EPIC cohort.
    Int J Cancer. 2015 Feb 5. doi: 10.1002/ijc.29471.
    PubMed     Text format     Abstract available


    January 2015
  32. MASOUMI-MOGHADDAM S, Amini A, Wei AQ, Robertson G, et al
    Sprouty 2 protein, but not Sprouty 4, is an independent prognostic biomarker for human epithelial ovarian cancer.
    Int J Cancer. 2015 Jan 13. doi: 10.1002/ijc.29425.
    PubMed     Text format     Abstract available


    December 2014
  33. HUANG Z, Gao Y, Wen W, Li H, et al
    Contraceptive methods and ovarian cancer risk among Chinese women: A report from the Shanghai women's health study.
    Int J Cancer. 2014 Dec 29. doi: 10.1002/ijc.29412.
    PubMed     Text format     Abstract available


  34. IV SANTALIZ-RUIZ LE, Xie X, Old M, Teknos TN, et al
    Emerging role of nanog in tumorigenesis and cancer stem cells.
    Int J Cancer. 2014;135:2741-8.
    PubMed     Text format     Abstract available


  35. SCHOCK H, Fortner RT, Surcel HM, Grankvist K, et al
    Early pregnancy IGF-I and placental GH and risk of epithelial ovarian cancer: A nested case-control study.
    Int J Cancer. 2014 Dec 8. doi: 10.1002/ijc.29387.
    PubMed     Text format     Abstract available


  36. KOTSOPOULOS J, Lubinski J, Gronwald J, Cybulski C, et al
    Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Int J Cancer. 2014 Dec 6. doi: 10.1002/ijc.29386.
    PubMed     Text format     Abstract available


  37. MATTE I, Lane D, Laplante C, Garde-Granger P, et al
    Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms.
    Int J Cancer. 2014 Dec 6. doi: 10.1002/ijc.29385.
    PubMed     Text format     Abstract available


    November 2014
  38. INOUE-CHOI M, Jones RR, Anderson KE, Cantor KP, et al
    Nitrate and nitrite ingestion and risk of ovarian cancer among postmenopausal women in Iowa.
    Int J Cancer. 2014 Nov 27. doi: 10.1002/ijc.29365.
    PubMed     Text format     Abstract available


  39. LEE JW, Ryu JY, Yoon G, Jeon HK, et al
    Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer.
    Int J Cancer. 2014 Nov 27. doi: 10.1002/ijc.29362.
    PubMed     Text format     Abstract available


    October 2014
  40. LEE EK, Song KA, Chae JH, Kim KM, et al
    GAGE12 mediates human gastric carcinoma growth and metastasis.
    Int J Cancer. 2014 Oct 23. doi: 10.1002/ijc.29286.
    PubMed     Text format     Abstract available


    July 2014
  41. LHEUREUX S, N'Diaye M, Blanc-Fournier C, Dugue AE, et al
    Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.
    Int J Cancer. 2014 Jul 28. doi: 10.1002/ijc.29104.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: